Filter Results
:
(1,001)
Show Results For
-
All HBS Web
(1,001)
- People (4)
- News (249)
- Research (603)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
Show Results For
-
All HBS Web
(1,001)
- People (4)
- News (249)
- Research (603)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
- October 2005 (Revised January 2021)
- Case
Pharmaceutical Industry in 2005, The
By: John R. Wells and Elizabeth Raabe
The entire pharmaceutical industry faced uncertain times in 2005. Many of the industry's most pressing issues—patent expirations, new drug pipeline development, price pressures, regulatory issues, and political pressures—were long standing. Fundamentally new...
View Details
Keywords:
Strategy;
Research and Development;
Framework;
Change;
Competition;
Technological Innovation;
Pharmaceutical Industry
Wells, John R., and Elizabeth Raabe. "Pharmaceutical Industry in 2005, The." Harvard Business School Case 706-423, October 2005. (Revised January 2021.)
- 07 Jun 2023
- News
Martine Rothblatt: Making Implausible Dreams Reality
- January 2021
- Case
mPharma (A)
By: Rembrand Koning, John D. Macomber, Pippa Tubman Armerding and Wale Lawal
mPharma pioneered electronic prescriptions in Ghana, and aimed to increase drug affordability and accessibility in Africa, but the company remained unprofitable. Following investor concerns about mPharma's business, CEO Gregory Rockson considered alternative business...
View Details
Keywords:
Strategy;
Entrepreneurship;
Acquisition;
Health;
Business Model;
Health Industry;
Technology Industry;
Ghana
Koning, Rembrand, John D. Macomber, Pippa Tubman Armerding, and Wale Lawal. "mPharma (A)." Harvard Business School Case 721-428, January 2021.
- October 2012
- Supplement
Aqua Bounty Courseware
By: Lucy White and Steve Burn-Murdoch
Valuation of a pre-revenue biotech company at IPO using probability trees and real option techniques. Company is based in Massachusetts and lists in London on AIM. Products are genetically-modified fast-growing salmon for fish farmers and disease-prevention drugs and...
View Details
- February 2002 (Revised August 2002)
- Case
Inhale Therapeutics: Executing and Growing the Business Model
Inhale is about to bring a novel technology to market that uses inhalation to administer drugs that formerly required injection. Inhale must now decide which way to evolve its business model. This will determine the future direction of growth for the company.
View Details
Keywords:
Business Model;
Technological Innovation;
Health Care and Treatment;
Growth and Development Strategy;
Medical Devices and Supplies Industry
Chesbrough, Henry W., and Gillian Morris. "Inhale Therapeutics: Executing and Growing the Business Model." Harvard Business School Case 602-132, February 2002. (Revised August 2002.)
- September 1993
- Supplement
Manufacturing at ALZA: The Right Prescription? (C)
ALZA, a drug delivery company, considers marketing its own and other companies' products. The primary issue is whether to build an internal sales force focused on a few niche markets, to finance a sales force through alliances, or to acquire a marketing company.
View Details
Keywords:
Mergers and Acquisitions;
Product Marketing;
Alliances;
Research and Development;
Salesforce Management;
Business Strategy;
Pharmaceutical Industry
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (C)." Harvard Business School Supplement 694-021, September 1993.
- 06 Mar 2020
- News
How Medical Nonprofits Set Winning Strategy
- June 1996 (Revised February 1998)
- Case
Repositioning Ranbaxy
A leading Indian pharmaceutical company reacts to changes in its industry by trying to reposition along several dimensions from developing markets to developed ones, from bulk drugs toward pharmaceuticals in dosage forms, and from reverse-engineering products developed...
View Details
Keywords:
Organizational Change and Adaptation;
Expansion;
Industry Structures;
Pharmaceutical Industry;
India
Ghemawat, Pankaj, and Kazbi Kothavala. "Repositioning Ranbaxy." Harvard Business School Case 796-181, June 1996. (Revised February 1998.)
- 2024
- Working Paper
Chimeric Antigen Receptor T-Cell Therapy—Living Drugs: Case Histories of Transformational Advances
By: Amar Bhidé and Srikant M. Datar
In 2017, the US Food and Drug Administration (FDA) approved an immunotherapeutic treatment, called CAR-T therapy, for two kinds of blood cancers—acute leukemia (ALL) and a lymphoma. We describe 1) how CAR-T works, 2) the foundational advances and discoveries, 3) the...
View Details
Keywords:
Immunotherapy;
Health Care and Treatment;
Innovation and Invention;
Research and Development;
Governing Rules, Regulations, and Reforms
Bhidé, Amar, and Srikant M. Datar. "Chimeric Antigen Receptor T-Cell Therapy—Living Drugs: Case Histories of Transformational Advances." Harvard Business School Working Paper, No. 21-035, August 2020. (Revised May 2024.)
- January 2014 (Revised June 2014)
- Case
23andMe: Genetic Testing for Consumers (A)
By: John A. Quelch and Margaret L. Rodriguez
On November 22, 2013, the direct-to-consumer genetic testing provider, 23andMe, received a letter from the U.S. Food and Drug Administration (FDA) ordering the company to halt the sale and promotion of its genetic testing kit. The FDA stated that the product was...
View Details
Keywords:
Public Health;
Genome Testing;
Health Care;
Ancestry;
23andMe;
Marketing;
Product Launch;
Health;
Health Care and Treatment;
Health Testing and Trials;
Genetics;
Strategy;
Health Industry;
United States
Quelch, John A., and Margaret L. Rodriguez. "23andMe: Genetic Testing for Consumers (A)." Harvard Business School Case 514-086, January 2014. (Revised June 2014.)
- 16 Jan 2018
- First Look
First Look at New Research and Ideas, January 16, 2018
https://www.hbs.edu/faculty/Pages/item.aspx?num=53705 Developing Novel Drugs By: Krieger, Joshua, Danielle Li, and Dimitris Papanikolaou Abstract—We analyze firms' decisions to invest in incremental and radical innovation, focusing...
View Details
Keywords:
Sean Silverthorne
- 11 Jun 2018
- News
How science can bring about a eureka moment for Indian startups
- September 2012 (Revised January 2014)
- Case
Aqua Bounty
By: Lucy White and Stephen Burn-Murdoch
Valuation of a pre-revenue biotech company at IPO using probability trees and real option techniques. Company is based in Massachusetts and lists in London on AIM. Products are genetically-modified fast-growing salmon for fish farmers and disease-prevention drugs and...
View Details
Keywords:
IPO;
Valuation;
Real Options;
Decision Tree;
Biotech;
Genetically Modified;
Salmon;
Entrepreneurship;
Finance;
Agriculture and Agribusiness Industry;
Biotechnology Industry;
North and Central America;
Europe;
South America
White, Lucy, and Stephen Burn-Murdoch. "Aqua Bounty." Harvard Business School Case 213-047, September 2012. (Revised January 2014.)
- 05 Mar 2019
- News
Female Faculty Leading the Conversation
- February 2024
- Case
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no...
View Details
Keywords:
Commercialization;
Corporate Strategy;
Competitive Strategy;
Product Launch;
Health Testing and Trials;
Research and Development;
Laws and Statutes;
Pharmaceutical Industry;
Europe;
United States;
United Kingdom
Zuzul, Tiona, Kisha Lashley, and Gamze Yucaoglu. "Compass Pathways: Pioneering Psychedelic Treatment." Harvard Business School Case 724-412, February 2024.
- October 2007 (Revised July 2013)
- Case
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech
By: Robert F. Higgins, Sophie LaMontagne and Brent Kazan
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to...
View Details
Keywords:
Philanthropy;
Philanthropy Funding;
Innovation;
Funding Model;
Venture Capital;
Partners and Partnerships;
Financing and Loans;
Investment Funds;
Acquisition;
Philanthropy and Charitable Giving;
Biotechnology Industry;
Pharmaceutical Industry;
San Diego
Higgins, Robert F., Sophie LaMontagne, and Brent Kazan. "Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech." Harvard Business School Case 808-005, October 2007. (Revised July 2013.)
- March 1999 (Revised June 2000)
- Case
Eli Lilly: The Evista Project
By: Steven C. Wheelwright and Matt Verlinden
Describes the creation and operation of the initial two heavyweight teams for new drug development and launch. The primary focus is on one of the teams, Evista, although comparisons to the other team, Zyprexa, are included. Lilly must decide the next phase (postlaunch)...
View Details
Keywords:
Projects;
Groups and Teams;
Operations;
Management Teams;
Product Development;
Transition;
Product Design;
Business Startups;
Business Plan;
Product Launch;
Competition;
Service Operations;
Pharmaceutical Industry
Wheelwright, Steven C., and Matt Verlinden. "Eli Lilly: The Evista Project." Harvard Business School Case 699-016, March 1999. (Revised June 2000.)
- May 2002 (Revised October 2005)
- Case
Marketing Antidepressants: Prozac and Paxil
By: Youngme E. Moon and Kerry Herman
Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to...
View Details
Keywords:
Patents;
Product Positioning;
Competition;
Ethics;
Value;
Health Care and Treatment;
Brands and Branding;
Pharmaceutical Industry;
United States
Moon, Youngme E., and Kerry Herman. "Marketing Antidepressants: Prozac and Paxil." Harvard Business School Case 502-055, May 2002. (Revised October 2005.)
- January 2001
- Case
Merck Global Health Initiatives (B): Botswana
By: James E. Austin, Diana Barrett and James Weber
The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,...
View Details
Keywords:
Health Disorders;
Health Care and Treatment;
Private Sector;
Public Sector;
Alliances;
Problems and Challenges;
Africa;
Botswana
Austin, James E., Diana Barrett, and James Weber. "Merck Global Health Initiatives (B): Botswana." Harvard Business School Case 301-089, January 2001.
- 15 Mar 2019
- News